500 related articles for article (PubMed ID: 29630890)
1. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
[TBL] [Abstract][Full Text] [Related]
2. Neuromodulation and female pelvic disorders.
Noblett K
Curr Opin Urol; 2016 Jul; 26(4):321-7. PubMed ID: 27070647
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation for fecal incontinence in Latin America: initial results of a multicenter study.
Oliveira L; Hagerman G; Torres ML; Lumi CM; Siachoque JAC; Reyes JC; Perez-Aguirre J; Sanchez-Robles JC; Guerrero-Guerrero VH; Regadas SM; Filho VG; Rosato G; Vieira E; Marzan L; Lima D; Londoño-Schimmer E; Wexner SD
Tech Coloproctol; 2019 Jun; 23(6):545-550. PubMed ID: 31190233
[TBL] [Abstract][Full Text] [Related]
6. Prolonged percutaneous SNM testing does not cause infection-related explanation.
Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Surgical Site Infection in Patients Undergoing Sacral Nerve Modulation Therapy.
Brueseke T; Livingston B; Warda H; Osann K; Noblett K
Female Pelvic Med Reconstr Surg; 2015; 21(4):198-204. PubMed ID: 26052646
[TBL] [Abstract][Full Text] [Related]
8. First-in-human implantation of a mid-field powered neurostimulator at the sacral nerve: Results from an acute study.
van Kerrebroeck PEVA; Reekmans M; van Koeveringe GA; Yeh AJ; Fayram TA; Sharan AD; Comiter CV
Neurourol Urodyn; 2019 Aug; 38(6):1669-1675. PubMed ID: 31107559
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Sacral Nerve Stimulation Device Revision and Explantation in a Single Center, Multidisciplinary Study.
Gevelinger MM; Sanderson DJ; Jaworski E; Doyle PJ
Neuromodulation; 2020 Dec; 23(8):1201-1206. PubMed ID: 31697433
[TBL] [Abstract][Full Text] [Related]
10. Sacral Neuromodulation: Determining Predictors of Success.
Morgan TN; Pace N; Mohapatra A; Ren D; Kunkel G; Tennyson L; Shepherd JP; Chermansky CJ
Urology; 2021 Jul; 153():124-128. PubMed ID: 32619594
[TBL] [Abstract][Full Text] [Related]
11. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults.
Herbison GP; Arnold EP
Cochrane Database Syst Rev; 2009 Apr; (2):CD004202. PubMed ID: 19370596
[TBL] [Abstract][Full Text] [Related]
13. Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005-2011).
Dobberfuhl AD; Mahal A; Dallas KB; Choi KM; Comiter CV; Elliott CS
Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):437-442. PubMed ID: 30059438
[TBL] [Abstract][Full Text] [Related]
14. Neuromodulation in urology, state of the art.
Ammirati E; Giammò A; Manassero A; Carone R
Urologia; 2019 Nov; 86(4):177-182. PubMed ID: 31368415
[TBL] [Abstract][Full Text] [Related]
15. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?
High RA; Winkelman W; Panza J; Sanderson DJ; Yuen H; Halder G; Shaver C; Bird ET; Rogers RG; Danford JM
Int Urogynecol J; 2021 Jan; 32(1):149-157. PubMed ID: 32588075
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections.
Sohail MR; Hussain S; Le KY; Dib C; Lohse CM; Friedman PA; Hayes DL; Uslan DZ; Wilson WR; Steckelberg JM; Baddour LM;
J Interv Card Electrophysiol; 2011 Aug; 31(2):171-83. PubMed ID: 21365264
[TBL] [Abstract][Full Text] [Related]
17. The management of endograft infections following endovascular thoracic and abdominal aneurysm repair.
Murphy EH; Szeto WY; Herdrich BJ; Jackson BM; Wang GJ; Bavaria JE; Fairman RM; Woo EY
J Vasc Surg; 2013 Nov; 58(5):1179-85. PubMed ID: 23830947
[TBL] [Abstract][Full Text] [Related]
18. Pediatric sacral nerve stimulator explanation due to complications or cure: a survival analysis.
Rensing AJ; Szymanski KM; Dunn S; King S; Cain MP; Whittam BM
J Pediatr Urol; 2019 Feb; 15(1):39.e1-39.e6. PubMed ID: 30473473
[TBL] [Abstract][Full Text] [Related]
19. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
Noblett K; Benson K; Kreder K
Neurourol Urodyn; 2017 Apr; 36(4):1136-1139. PubMed ID: 27491027
[TBL] [Abstract][Full Text] [Related]
20. What Is New in Neuromodulation?
Moore CK; Rueb JJ; Derisavifard S
Curr Urol Rep; 2019 Aug; 20(9):55. PubMed ID: 31388779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
